BACKGROUND
Pediatric autoimmune liver disease, including autoimmune hepatitis (AIH) and autoimmune sclerosing cholangitis (ASC), is a group of chronic liver conditions requiring life‐long management. 1 The medical management involves long‐term use of corticosteroids with or without immunosuppressive therapy, both of which carry risk of side effects. Some children do not respond to standard therapy and liver disease may progress, ultimately requiring a liver transplant. Continued medication adherence and clinical follow‐up are two essential factors in long‐term disease management.
PSYCHOSOCIAL IMPACT
Several studies have demonstrated that youth with autoimmune liver disease report lower health‐related quality of life (HRQOL) than healthy controls. 2 Higher levels of mental health concerns are associated with lower treatment adherence in these youth, although the causal direction of this relationship is unclear. 3 Although research is sparse in pediatrics, rates of depression and anxiety are known to be higher in adults with AIH compared to the general population. 4
Similar to other chronic illnesses, emotional distress and impairment associated with adjustment to AIH is likely related to a variety of factors, including the necessity for frequent medical visits and medication management challenges. 5 Additional psychosocial considerations for pediatric AIH include the uncertainty and fear around prognosis or disease progression (e.g., potential for necessity of liver transplant later in life), as well as unpleasant side effects of corticosteroids known to affect HRQOL 6 and which may affect adherence. In studies of diseases with similar disease‐related uncertainty, such as inflammatory bowel disease (IBD), higher rated levels of uncertainty are related to poorer adjustment to illness 7 and increase in depressive symptoms. 8
Given the chronic nature of AIH, the potential for disease progression, and necessity for long‐term medication use and consistent medical follow‐up, psychosocial considerations are an important but underappreciated aspect of care.
STRATEGIES FOR ADDRESSING WELLBEING AND ADHERENCE
To mitigate the effect of AIH on quality of life and promote treatment adherence, medical professionals can consider the following recommendations. Strategies should be considered within two areas: proactively addressing psychosocial concerns and interventions for identified concerns.
Proactive considerations
Managing uncertainty
Addressing ambiguity regarding disease progression (e.g., future necessity of liver transplant) can occur through proactive discussions with children and caregivers. Even when gastroenterologists cannot provide definitive information regarding prognosis, it is helpful to allocate time to listen and validate patient concerns. Additional strategies include encouraging families to focus on aspects of disease management that are within their control by developing specific and attainable behavioral goals (e.g., daily medication reminders and attending follow‐up appointments). By emphasizing behavioral successes, providers can support patients and families in feeling accomplished with their participation in disease management, thereby reducing distress and impairment. 9
Psychoeducation
Gastroenterologists/hepatologists are encouraged to discuss psychological and functional aspects of AIH at the time of diagnosis to mitigate its impact. Psychoeducation should involve explicitly outlining activities in which the patient can still participate (and encouraging this participation; e.g., school, sports, travel), problem‐solving barriers to participation, and identifying systems of social support and engagement with the AIH community. Adherence to medications, participation in a child's usual activities, and cultivating a strong system of social support can be protective against adverse psychosocial impacts of chronic illness. 10 Additionally, adherence to medications may be negatively impacted by distressing side effects of corticosteroids. A discussion of potential side effects, and plan for mitigation, should occur between provider and patient.
During initial psychoeducation discussions, it is important for medical providers to create a safe and comfortable environment for families to ask questions and express concerns. This conversation can be fostered by withholding judgment and answering questions earnestly and thoughtfully. A supportive discussion promotes patient trust in the medical team and improves patients' recall of important treatment information. 11
Assessment
Proactive strategies can also include assessment of risk factors that may contribute to poor disease adjustment. Youth demonstrating more pre‐morbid challenges (e.g., behavioral or emotional concerns, limited access to resources) may have more difficulty adjusting to the chronic illness diagnosis and management. 12 The assessment should include questions about pre‐morbid behavioral and emotional functioning (of both parent and youth), logistical/socioeconomic barriers (e.g., health insurance, transportation), health literacy, family functioning, and social support. Assessment tools, such as the PedsQL Medicines Scale, 13 are available. Additionally, the child's developmental stage should be considered when evaluating and intervening on psychosocial factors in AIH (e.g., Reference 14 ). For younger children, assessing parental functioning may be a priority, whereas for older adolescents, evaluating and intervening at the level of the adolescent patient should be prioritized. This assessment can help providers to direct patients and their families to appropriate supports (Table 1).
TABLE 1.
Challenge | Potential impact on AIH management | Strategies for medical teams | Referral |
---|---|---|---|
Logistical and Socioeconomic
|
Adherence Challenges: limited resources and necessity for prioritization of basic needs (e.g., having housing), attending visits may not be logistically feasible (e.g., time of work) Impact on Wellbeing: added stress to existing challenges with basic needs |
|
Social work: Help to find resources Disability services: Connect with Medicaid, other statewide supports, school accommodations |
Health Literacy and Knowledge
|
Adherence Challenges: difficulty problem‐solving and advocating, not taking medication when feeling well, avoidance of health‐care visits, lack of understanding of necessity of seeking health‐care Impact on Wellbeing: more uncertainty and related distress |
|
Social work: teach health literacy, assist in health‐care management Disability advocate: assist in health‐care management |
Mental Health
|
Adherence Challenges: lack of motivation or organization, limited reminders from parents Impact on Wellbeing: More intense emotional concerns surrounding diagnosis, prognosis, and disease progression |
|
Behavior therapist: teach behavioral techniques to increase healthy behaviors, problem‐solving, address mood concerns Counselor: teach to coping skills for chronic illness PCP or psychiatrist: prescribe psychiatric medications |
Social Support
|
Adherence Challenges: family conflict increasing child oppositional behavior, lack of organization, limited help with management behaviors Impact on Wellbeing: Caregivers or child may become more overwhelmed with managing chronic illness, feel alone in disease management |
|
Parent and child support groups: increase social support Family therapist: address family conflict and functioning |
Health‐care transition (HCT)
Assessment of health‐care self‐management and provision of corresponding interventions is also warranted for AIH patients nearing adulthood. HCT is the process of assessing, educating, and supporting young people as they prepare to move from child‐ to adult‐centered health‐care. Studies have found that higher rates of medical non‐adherence and increased morbidity and mortality occur immediately following the transition to adult care in chronic disease populations similar to AIH (e.g., IBD; 15 ). Poor adherence, poor disease management, and limited disease knowledge have been noted by adult hepatologists as the greatest barriers to optimal health‐care transition, and these challenges can be related to poor/limited preparation for transition. 16 To improve the transition period, experts recommend implementing a systematic transition policy, frequent assessment of adolescents' transition readiness and barriers (e.g., knowledge, financial), and a planned process for education and counseling of adolescents and young adults nearing transfer to adult gastroenterology. 16 Recommendations for assessment and transition planning are summarized in Table 2.
TABLE 2.
Key area for transition readiness | Disease and medication knowledge | Autonomy/independence in health‐care management | Health and lifestyle |
---|---|---|---|
Health‐care engagement by age—individualized consideration should be made for developmentally‐appropriate expectations based on cognitive and social–emotional functioning | |||
Early adolescence (12–14) |
|
|
|
Mid adolescence (14–17) |
|
|
|
Late adolescence (17+) |
|
|
|
Role of Medical Provider/Team |
|
|
|
Clinic HCT Guidelines | Six Core Elements to establish a HCT Program (GotTransition.org): | ||
| |||
Transition readiness assessments |
Transition Readiness Assessment Questionnaire (TRAQ; 17 )—A 29‐item patient‐report measure with two domains: self‐management and self‐advocacy STARx questionnaire 18 —An 18‐item patient‐ and parent‐ report measure with three subdomains: communication with medical provider, disease knowledge, and self‐management Transition Readiness Assessment from Got Transition |
Note: Information in this table was adapted from Got Transition, NASPGHN Healthcare Provider Transitioning Checklist, and Improve Care Now.
Interventions for identified concerns
Adherence challenges
Addressing difficulties with adherence to medication regimens is not a one‐size‐fits‐all approach. These challenges may vary depending on family factors, including patient and caregivers' knowledge and understanding of the disease, psychological barriers (e.g., mental health concerns, stigma, uncertainty), and logistical barriers. 11 Individualization of interventions is recommended based on an assessment of relevant adherence barriers. 19 It is common for multiple barriers to interact, leading to a necessity for more complex interventions. For example, the uncertainty regarding medication efficacy and disease progression may lead to low prioritization of treatment regimens (psychological and medical barriers). This challenge may be further complicated for a family with limited resources who may allocate finances to other critical necessities (a logistical barrier). If multiple or interacting barriers are identified, connecting the family with social work or behavioral health/psychology may be warranted (Table 1).
Mental health and emotional distress
Patients and families may endorse or display difficulty coping with AIH at follow‐up visits. Although emotional distress related to a chronic illness is common and at times expected, an assessment of these concerns is crucial to identify patients requiring additional support. Given that patients and families may be hesitant to start a conversation about mental health concerns with their medical provider, physicians can begin by conducting a brief assessment. This assessment may include questions about mood, fears, daily functioning (e.g., school, friends, and hobbies), sleep, and coping strategies. For youth and families with expected levels of emotional distress, feeling heard, validated, and supported by their gastroenterologist is often sufficient. 11 If a medical provider is concerned about more acute emotional distress or disruption to daily functioning, they are encouraged to consult with a mental health provider, preferably a professional with training in pediatric chronic health conditions. If a child is experiencing severe functional impairment (e.g., anxiety, avoidance of activities, symptoms of depression or post‐traumatic stress) referral to a mental health provider is recommended.
SUMMARY
The management of pediatric autoimmune liver disease, similar to other pediatric chronic illnesses, is impacted by psychological and social factors of youth and their families. Medical teams can mitigate psychosocial distress and barriers to medical adherence through brief assessments and supportive care strategies.
CONFLICT OF INTEREST
Nothing to report.
Wellen BCM, Lin HC, Stellway JE. Psychosocial considerations in pediatric autoimmune liver disease. Clinical Liver Disease. 2022;20:124–129. 10.1002/cld.1238
REFERENCES
- 1. Jiménez‐Rivera C, Ling SC, Ahmed N, Yap J, Aglipay M, Barrowman N, et al. Incidence and characteristics of autoimmune hepatitis. Pediatrics. 2015;136(5):1237–48. [DOI] [PubMed] [Google Scholar]
- 2. de Carvalho Trevizoli I, Pinedo CS, Teles VO, de Melo Seixas RBP, de Carvalho E. Autoimmune hepatitis in children and adolescents: effect on quality of life. J Pediatr Gastroenterol Nutr. 2018;66(6):861–5. [DOI] [PubMed] [Google Scholar]
- 3. Sockalingam S, Blank D, Abdelhamid N, Abbey SE, Hirschfield GM. Identifying opportunities to improve management of autoimmune hepatitis: evaluation of drug adherence and psychosocial factors. J Hepatol. 2012;57(6):1299–304. [DOI] [PubMed] [Google Scholar]
- 4. Schramm C, Wahl I, Weiler‐Normann C, Voigt K, Wiegard C, Glaubke C, et al. Health‐related quality of life, depression, and anxiety in patients with autoimmune hepatitis. J Hepatol. 2014;60(3):618–24. [DOI] [PubMed] [Google Scholar]
- 5. Varni J, Limbers C, Burwinkle T. Impaired health‐related quality of life in children and adolescents with chronic conditions: a comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQLTM 4.0 Generic Core Scales. Health Qual Life Outcome. 2007;5:43. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Bozzini AB, Neder L, Silva CA, Porta G. Decreased health‐related quality of life in children and adolescents with autoimmune hepatitis. J Pediatr (Rio J). 2019;95:87–93. [DOI] [PubMed] [Google Scholar]
- 7. Roberts CM, Gamwell KL, Baudino MN, Perez MN, Delozier AM, Sharkey CM, et al. Youth and parent illness appraisals and adjustment in pediatric inflammatory bowel disease. J Dev Phys Disabilities. 2019;31(6):777–90. [Google Scholar]
- 8. Baudino MN, Gamwell KL, Roberts CM, Grunow JE, Jacobs NJ, Gillaspy SR, et al. Disease severity and depressive symptoms in adolescents with inflammatory bowel disease: The mediating role of parent and youth illness uncertainty. J Pediatr Psychol. 2019;44(4):490–8. [DOI] [PubMed] [Google Scholar]
- 9. Cristello Sarteau A, Crandell J, Seid M, Kichler JC, Maahs DM, Wang J, et al. Characterization of youth goal setting in the self‐management of type 1 diabetes and associations with HbA1c: The Flexible Lifestyle Empowering Change trial. Pediatr Diabetes. 2020;21(7):1343–52. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Sansom‐Daly UM, Peate M, Wakefield CE, Bryant RA, Cohn RJ. A systematic review of psychological interventions for adolescents and young adults living with chronic illness. Health Psychol. 2012;31(3):380–93. [DOI] [PubMed] [Google Scholar]
- 11. DiMatteo MR, Haskard‐Zolnierek KB, Martin LR. Improving patient adherence: a three‐factor model to guide practice. Health Psychol Rev. 2012;6(1):74–91. [Google Scholar]
- 12. Touma N, Varay C, Baeza‐Velasco C. Determinants of quality of life and psychosocial adjustment to pediatric inflammatory bowel disease: a systematic review focused on Crohn's disease. J Psychosom Res. 2021;142:110354. [DOI] [PubMed] [Google Scholar]
- 13. Varni JW, Bendo CB, Denham J, Shulman RJ, Self MM, Neigut DA, et al. PedsQL gastrointestinal symptoms module: feasibility, reliability, and validity. J Pediatr Gastroenterol Nutr. 2014;59(3):347–55. [DOI] [PubMed] [Google Scholar]
- 14. Darcy A, Samyn M. Looking after young people with liver conditions: understanding chronic illness management in the context of adolescent development. Clinical Liver Disease. 2017;9(5):103–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Bennett AL, Moore D, Bampton PA, Bryant RV, Andrews JM. Outcomes and patients' perspectives of transition from paediatric to adult care in inflammatory bowel disease. World J Gastroenterol. 2016;22(8):2611–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Vajro P, Fischler B, Burra P, Debray D, Dezsofi A, Nuzio SG,ṣet al. The health care transition of youth with liver disease into the adult health system: position paper from ESPGHAN and EASL. J Pediatr Gastroenterol Nutr. 2018;66(6):976–90. [DOI] [PubMed] [Google Scholar]
- 17. Wood DL, Sawicki GS, Miller MD, Smotherman C, Lukens‐Bull K, Livingood WC, et al. The Transition Readiness Assessment Questionnaire (TRAQ): its factor structure, reliability, and validity. Academy of Pediatrics. 2014;14(4):415–22. [DOI] [PubMed] [Google Scholar]
- 18. Nazareth M, Hart L, Ferris M, Rak E, Hooper S, van Tilburg MA. A parental report of youth transition readiness: the parent STARx questionnaire (STARx‐P) and re‐evaluation of the STARx child report. J Pediatr Nurs. 2018;38:122–6. [DOI] [PubMed] [Google Scholar]
- 19. Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013;4:91. [DOI] [PMC free article] [PubMed] [Google Scholar]